-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Resonated by multiple factors such as favorable policies, influx of talents, capital increase, and increased investment in corporate R&D, China's pharmaceutical industry is developing continuously
.
In this context, the development of the entire pharmaceutical equipment industry has also begun to continue to improve
.
It is understood that in recent years, the performance of a large number of pharmaceutical machine companies has shown a rising trend
.
For example, in 2021, the performance report cards of most listed pharmaceutical machine companies are very bright, especially the leading companies, which have outstanding performance, and their net profit has increased significantly
.
Technological innovation is bringing "new vitality" to pharmaceutical equipment companies (Source: Pharmaceutical Network) For example, on January 10, Tofflon's 2021 performance pre-increase announcement showed that the expected net profit is 765 million yuan to 9.
04 yuan.
100 million yuan, and the net profit increased by 65.
00%~95.
00% year-on-year
.
In addition, Xinhua Medical announced that its net profit in 2021 is expected to be 530 million yuan to 636 million yuan, an increase of 295.
86 million yuan to 401.
86 million yuan compared with the same period last year (statutory disclosure data), a year-on-year increase of 126.
36% to 171.
63%
.
On the whole, because the leading enterprises have more advantages in resources, R&D, technology, etc.
, as the pharmaceutical equipment industry ushered in a new round of opportunities, the industry generally believes that the pharmaceutical machines represented by Chutian Technology and Tofflon, etc.
Giants will also benefit significantly in the future
.
However, at the same time, the competition among the major pharmaceutical machine companies will also become more and more intense
.
It is understood that in order to occupy more market share in the future market, many companies are taking the pulse of the market development trend and actively deploying, such as expanding the talent team internally, increasing investment in innovation and R&D, expanding production capacity, deploying in the field of biological drugs, and improving externally.
After-sales service level, speed up internationalization,
etc.
It is worth mentioning that among many layouts, accelerating innovation has obviously become the focus of the development of most pharmaceutical machine companies
.
A large number of pharmaceutical machine companies are accelerating the R&D and upgrading of intelligent and information-based equipment through innovation, and are making efforts to the high-end market
.
As far as I know, among them, Chutian Technology has been committed to building a new model of intelligent manufacturing
.
At present, it has achieved fruitful results in the field of medical equipment and high-end manufacturing
.
For example, in the TOP workshop, its sterile robot can automatically complete the unpacking and material transfer of prefilled syringes, and integrate tearing, inner paper, filling, and plugging into one.
The finished drug appears at the end point
.
According to reports, this is a world-class intelligent robot for aseptic production of medicines.
Without manual intervention, the probability of drug contamination is greatly reduced.
More importantly, the entire cycle of drug production has been digitized and can be traced throughout the process
.
Due to technological innovation, it has tasted the sweetness of development.
Therefore, Chutian Technology has continued to increase R&D investment in recent years.
At present, its R&D investment has accounted for nearly 10% of its revenue, and it has created a professional team.
The R&D team has more than 2,400 valid patents
.
It is worth mentioning that, in addition to continuing to increase investment in research and development, Chutian Technology has always attached great importance to the cultivation of skilled talents and the cultivation of craftsmanship.
cooperation
.
In addition, Tofflon also conforms to the development trend of China's manufacturing industry transformation.
Since the beginning of the 21st century, Tofflon has taken firm steps of exploration in product research and development and proactively meeting customer needs, from stand-alone freeze dryer production to professional pharmaceutical engineering systems.
Manufacturing, from the expansion of product functions to the upgrading of internal production technology, Tofflon has always been on the road of intelligence and informatization
.
In general, the industry believes that only by shifting to the high-end in the value chain, enhancing innovation and design capabilities, building independent brands, continuously improving the differentiation of customer groups, and actively responding to more complex customer needs, can Chinese manufacturing companies welcome more development opportunities
.
Judging from the fact that a large number of domestic pharmaceutical machinery enterprises are carrying out new strategic layouts through accelerated innovation, the research and development of high-end and intelligent pharmaceutical equipment will become the main development direction of most pharmaceutical equipment enterprises for a long period of time in the future, and will also make them welcome more new opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In this context, the development of the entire pharmaceutical equipment industry has also begun to continue to improve
.
It is understood that in recent years, the performance of a large number of pharmaceutical machine companies has shown a rising trend
.
For example, in 2021, the performance report cards of most listed pharmaceutical machine companies are very bright, especially the leading companies, which have outstanding performance, and their net profit has increased significantly
.
Technological innovation is bringing "new vitality" to pharmaceutical equipment companies (Source: Pharmaceutical Network) For example, on January 10, Tofflon's 2021 performance pre-increase announcement showed that the expected net profit is 765 million yuan to 9.
04 yuan.
100 million yuan, and the net profit increased by 65.
00%~95.
00% year-on-year
.
In addition, Xinhua Medical announced that its net profit in 2021 is expected to be 530 million yuan to 636 million yuan, an increase of 295.
86 million yuan to 401.
86 million yuan compared with the same period last year (statutory disclosure data), a year-on-year increase of 126.
36% to 171.
63%
.
On the whole, because the leading enterprises have more advantages in resources, R&D, technology, etc.
, as the pharmaceutical equipment industry ushered in a new round of opportunities, the industry generally believes that the pharmaceutical machines represented by Chutian Technology and Tofflon, etc.
Giants will also benefit significantly in the future
.
However, at the same time, the competition among the major pharmaceutical machine companies will also become more and more intense
.
It is understood that in order to occupy more market share in the future market, many companies are taking the pulse of the market development trend and actively deploying, such as expanding the talent team internally, increasing investment in innovation and R&D, expanding production capacity, deploying in the field of biological drugs, and improving externally.
After-sales service level, speed up internationalization,
etc.
It is worth mentioning that among many layouts, accelerating innovation has obviously become the focus of the development of most pharmaceutical machine companies
.
A large number of pharmaceutical machine companies are accelerating the R&D and upgrading of intelligent and information-based equipment through innovation, and are making efforts to the high-end market
.
As far as I know, among them, Chutian Technology has been committed to building a new model of intelligent manufacturing
.
At present, it has achieved fruitful results in the field of medical equipment and high-end manufacturing
.
For example, in the TOP workshop, its sterile robot can automatically complete the unpacking and material transfer of prefilled syringes, and integrate tearing, inner paper, filling, and plugging into one.
The finished drug appears at the end point
.
According to reports, this is a world-class intelligent robot for aseptic production of medicines.
Without manual intervention, the probability of drug contamination is greatly reduced.
More importantly, the entire cycle of drug production has been digitized and can be traced throughout the process
.
Due to technological innovation, it has tasted the sweetness of development.
Therefore, Chutian Technology has continued to increase R&D investment in recent years.
At present, its R&D investment has accounted for nearly 10% of its revenue, and it has created a professional team.
The R&D team has more than 2,400 valid patents
.
It is worth mentioning that, in addition to continuing to increase investment in research and development, Chutian Technology has always attached great importance to the cultivation of skilled talents and the cultivation of craftsmanship.
cooperation
.
In addition, Tofflon also conforms to the development trend of China's manufacturing industry transformation.
Since the beginning of the 21st century, Tofflon has taken firm steps of exploration in product research and development and proactively meeting customer needs, from stand-alone freeze dryer production to professional pharmaceutical engineering systems.
Manufacturing, from the expansion of product functions to the upgrading of internal production technology, Tofflon has always been on the road of intelligence and informatization
.
In general, the industry believes that only by shifting to the high-end in the value chain, enhancing innovation and design capabilities, building independent brands, continuously improving the differentiation of customer groups, and actively responding to more complex customer needs, can Chinese manufacturing companies welcome more development opportunities
.
Judging from the fact that a large number of domestic pharmaceutical machinery enterprises are carrying out new strategic layouts through accelerated innovation, the research and development of high-end and intelligent pharmaceutical equipment will become the main development direction of most pharmaceutical equipment enterprises for a long period of time in the future, and will also make them welcome more new opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
